Obesity Drug Market Evolution Poses Coverage and Affordability Challenges for Medicaid MCOs

Industry experts predict obesity medications will face commoditization as new entrants arrive, while widespread payer coverage remains structurally difficult due to high prevalence and budget impact at scale. With roughly 55% of new obesity GLP-1 prescriptions currently self-pay and employers emerging as key coverage decision-makers for commercial populations, Medicaid managed care organizations face growing pressure to manage utilization and costs through prior authorization and step therapy as demand increases among a beneficiary population with high obesity rates but limited ability to pay out-of-pocket.

Pharmacy · Managed Care

This is outside commentary from Guidehouse, not part of Medicaid Monitor's independently scored news coverage.

More from Guidehouse